Plasma and CSF HVA before and after pharmacological treatment

Sharma, Rajiv P.; Javaid, Javaid I.; Janicak, Philip G.; Faull, Kym F.; Comaty, Joseph E.; Davis, John M.

doi:10.1016/0165-1781(89)90201-1

Cited by 57 publications

(27 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interactions between the two systems have been well studied in the CSF and plasma of schizophrenic patients through their respective metabolites: the dopamine metabolite homovanillic acid (HVA) and the norepinephrine metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG). Plasma HVA has been shown to reflect central or brain dopamine activity through studies in animals and humans (Bacopoulos et al 1979;Kendler et al 1982;Maas et al 1993;Lambert et al 1993;Amin et al 1992), indicating that 11-35% of plasma HVA comes from the brain.Several studies of schizophrenia have noted that the behavioral response to antipsychotic drugs (i.e., a decrease in psychosis levels) parallels a decrease in plasma HVA levels in schizophrenic patients over time (Pickar et al 1984(Pickar et al , 1986Davidson and Davis 1988;Davila et al 1988;Mazure et al 1991;Sharma et al 1989). Some studies have reported an initial increase in plasma HVA in the first week of antipsychotic drug From the VA Pittsburgh Healthcare System (MEK, JKY, DPvK), Pittsburgh, Pennsylvania; and Western Psychiatric Institute and Clinic (JKY, DPvK), University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania.…”

mentioning

confidence: 99%

“…Several studies of schizophrenia have noted that the behavioral response to antipsychotic drugs (i.e., a decrease in psychosis levels) parallels a decrease in plasma HVA levels in schizophrenic patients over time (Pickar et al 1984(Pickar et al , 1986Davidson and Davis 1988;Davila et al 1988;Mazure et al 1991;Sharma et al 1989). Some studies have reported an initial increase in plasma HVA in the first week of antipsychotic drug From the VA Pittsburgh Healthcare System (MEK, JKY, DPvK), Pittsburgh, Pennsylvania; and Western Psychiatric Institute and Clinic (JKY, DPvK), University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania.…”

mentioning

confidence: 99%

“…Several studies of schizophrenia have noted that the behavioral response to antipsychotic drugs (i.e., a decrease in psychosis levels) parallels a decrease in plasma HVA levels in schizophrenic patients over time (Pickar et al 1984(Pickar et al , 1986Davidson and Davis 1988;Davila et al 1988;Mazure et al 1991;Sharma et al 1989). Some studies have reported an initial increase in plasma HVA in the first week of antipsychotic drug treatment that also parallels the decrease in psychosis (Davila et al 1988(Davila et al , 1995Duncan et al 1993), while others did not observe this effect (Pickar et al 1986).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Plasma Catecholamine Metabolites as Markers for Psychosis and Antipsychotic Response in Schizophrenia

Kelley

Yao

Kammen

1999

Neuropsychopharmacology

View full text Add to dashboard Cite

The objective of this study was to determine the association between the patterns of change in the dopaminergic metabolite plasma homovanillic acid (HVA), the noradrenergic metabolite The action of antipsychotic drugs on the dopamine system have led to many examinations of dopaminergic metabolites as possible markers for psychosis and antipsychotic response. However, it has also become clear that the noradrenergic system has extensive interactions with the dopamine system, and may also play a role in schizophrenia (Antelman and Caggiula 1977;Hornykiewicz 1982;van Kammen and Kelley 1991), and may play a key role in psychotic relapse (Ko et al., 1988;van Kammen et al. 1989van Kammen et al. , 1994van Kammen et al. , 1996a. Interactions between the two systems have been well studied in the CSF and plasma of schizophrenic patients through their respective metabolites: the dopamine metabolite homovanillic acid (HVA) and the norepinephrine metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG). Plasma HVA has been shown to reflect central or brain dopamine activity through studies in animals and humans (Bacopoulos et al. 1979;Kendler et al. 1982;Maas et al. 1993;Lambert et al. 1993;Amin et al. 1992), indicating that 11-35% of plasma HVA comes from the brain.Several studies of schizophrenia have noted that the behavioral response to antipsychotic drugs (i.e., a decrease in psychosis levels) parallels a decrease in plasma HVA levels in schizophrenic patients over time (Pickar et al. 1984(Pickar et al. , 1986Davidson and Davis 1988;Davila et al. 1988;Mazure et al. 1991;Sharma et al. 1989). Some studies have reported an initial increase in plasma HVA in the first week of antipsychotic drug From the VA Pittsburgh Healthcare System (MEK, JKY, DPvK), Pittsburgh, Pennsylvania; and Western Psychiatric Institute and Clinic (JKY, DPvK), University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania.Address correspondence to: Mary Kelley, MS, GIM (13OU), VA Pittsburgh H.S., University Drive C, Pittsburgh, PA 15240.Received March 27, 1998; revised July 24, 1998; accepted July 28, 1998. 604 M.E. Kelley et al. N EUROPSYCHOPHARMACOLOGY 1999 -VOL . 20 , NO . 6 treatment that also parallels the decrease in psychosis (Davila et al. 1988(Davila et al. , 1995Duncan et al. 1993), while others did not observe this effect (Pickar et al. 1986). Other studies of antipsychotic efficacy have focused on response status as the outcome measure and have shown that plasma HVA decreases were significant only in responders (Davidson et al. 1991a;Bowers et al. 1984;Chang et al. 1988;Van Putten et al. 1989). Some studies have shown that both plasma HVA and plasma MHPG decrease during neuroleptic treatment in those who respond favorably (Mazure et al. 1991;Bowers et al. 1984;Chang et al. 1990;Green et al. 1993).Higher pretreatment plasma HVA has been shown to predict better response (Mazure et al. 1991;Bowers et al. 1984Bowers et al. , 1986Chang et al. 1990;Duncan et al. 1993;Scheffer et al. 1994;van Kammen et al. 1996b), and faster time to r...

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

“…Several studies of schizophrenia have noted that the behavioral response to antipsychotic drugs (i.e., a decrease in psychosis levels) parallels a decrease in plasma HVA levels in schizophrenic patients over time (Pickar et al 1984(Pickar et al , 1986Davidson and Davis 1988;Davila et al 1988;Mazure et al 1991;Sharma et al 1989). Some studies have reported an initial increase in plasma HVA in the first week of antipsychotic drug treatment that also parallels the decrease in psychosis (Davila et al 1988(Davila et al , 1995Duncan et al 1993), while others did not observe this effect (Pickar et al 1986).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Plasma Catecholamine Metabolites as Markers for Psychosis and Antipsychotic Response in Schizophrenia

Kelley

Yao

Kammen

1999

Neuropsychopharmacology

View full text Add to dashboard Cite

show abstract

“…Other studies noted that the behavioral response to antipsychotic drugs (i.e., a decrease in psychosis levels) parallels a decrease in plasma HVA levels in schizophrenic patients over time (19)(20). However, plasma HVA derives from both central and peripheral areas and from both noradrenergic (NA) and dopaminergic transmissions.…”

Section: Pfcmentioning

confidence: 99%

The biochemical womb of schizophrenia: A review

Gaur

Sharma

et al. 2008

Indian J Clin Biochem

View full text Add to dashboard Cite

show abstract

“…1984;Sharma et al 1989;Hsiao et al 1993b;Kahn et al 1993;Wieselgren and Lindstrom 1998;) and the HVA/5-HIAA ratio (Wode-Helgodt et al 1977; Härn-ryd et al 1984;Hsiao et al 1993b;Kahn et al 1993) without significantly affecting CSF 5-HIAA concentrations. Interestingly, the increase of the HVA/5-HIAA ratio (Kahn et al 1993;Wieselgren and Lindstrom 1998), but not the increase of the HVA concentrations (Sedvall et al 1974;Kahn et al 1993;Sharma et al 1993), was found to be related to symptomatic improvement after treatment with typical antipsychotics, suggesting that the therapeutic effect of these antipsychotics is associated with changing DA function relative to 5-HT function, rather than changing DA function per se.…”

Section: The Mechanism Of Action Of Both Typical Antipsychotics and Tmentioning

confidence: 99%

The Effect of Olanzapine Treatment on Monoamine Metabolite Concentrations in the Cerebrospinal Fluid of Schizophrenic Patients

Scheepers

2001

Neuropsychopharmacology

View full text Add to dashboard Cite

The mechanism of action of both typical antipsychotics and the atypical antipsychotic, clozapine, may be related to the (changing) interaction of dopamine and serotonin in schizophrenia. This study examined the effect of olanzapine in schizophrenic patients on cerebrospinal fluid (CSF) metabolites of dopamine (homovanillic acid, HVA) and serotonin (5-hydroxyindoleacetic acid, 5-HIAA). Twentythree male schizophrenic patients, who were drug-free for at least 2 weeks (mean drug-free period of 35 days Ϯ 43; median 16 days), underwent a lumbar puncture (LP).Patients were subsequently treated with olanzapine 10 mg/ day for 6 weeks, after which the LP was repeated. CSF was assayed for It has long been postulated that the mechanism of action of antipsychotics is related to their ability to block dopamine 2 (DA 2 ) receptors (Creese et al. 1976; Carlsson 1978; Farde et al. 1988). However, since the introduction of the atypical antipsychotics, most notably clozapine, it has become clear that DA 2 receptor blockade alone is insufficient to explain the clinical potency of all antipsychotic drugs (Meltzer 1989; Davis et al. 1991;Lieberman et al. 1998). Instead, it has been proposed that the mechanism of action of antipsychotics is rooted in their ability to affect both DA and serotonin (5-hydroxytryptamine, 5-HT) systems in the brain or, more specifically, their interaction (Meltzer 1989;Hsiao et al. 1993a;Kahn et al. 1993;Szymanski et al. 1993;Schmidt et al. 1995;Kapur and Remington 1996;Lieberman et al. 1998). Indeed, DA and 5-HT are functionally (Agren et al. 1986;Risby et al. 1987;Kelland et al. 1990;Roth and Meltzer 1995;Iyer and Bradberry 1996;Lieberman et al. 1998;) and anatomically (Ternaux et al. 1977;Priestley et al. 1981;Hetey and Drescher 1986; Fibiger and Miller 1987;Törk 1991) 25 , NO . 4 The Effect of Olanzapine on HVA and 5-HIAA in CSF 469One way to examine DA and 5-HT systems in the brain is through measurement of their metabolites in cerebrospinal fluid (CSF), that is, homovanillic acid (HVA) and 5-hydroxyindole-acetic acid (5-HIAA), respectively. Several studies (Garelis and Sourkes 1973;Weir et al. 1973;Wood 1980;Andersen et al. 1981; Bertilsson et al. 1982;Stanley et al. 1985;Wester et al. 1990; cf. Banki and Molnar 1981;Potter and Manji 1993) have demonstrated that concentrations of HVA and 5-HIAA in CSF reliably reflect HVA and 5-HIAA concentrations in the brain. This suggests that CSF HVA and 5-HIAA concentrations reflect central DA and 5-HT turnover and thus can be used to examine the effects of antipsychotic drugs on these two neurotransmitters and their ratio in vivo (Agnati et al. 1995;Silver et al. 1996).It has been shown that typical antipsychotics, which predominantly block DA 2 receptors, increase CSF HVA concentrations (Wode-Helgodt et al. 1977; Härnryd et al. 1984;Sharma et al. 1989;Hsiao et al. 1993b;Kahn et al. 1993;Wieselgren and Lindstrom 1998;) and the HVA/5-HIAA ratio (Wode-Helgodt et al. 1977; Härn-ryd et al. 1984;Hsiao et al. 1993b;Kahn et al. 1993) without significantly ...

show abstract

Plasma and CSF HVA before and after pharmacological treatment

Cited by 57 publications

References 28 publications

Plasma Catecholamine Metabolites as Markers for Psychosis and Antipsychotic Response in Schizophrenia

Plasma Catecholamine Metabolites as Markers for Psychosis and Antipsychotic Response in Schizophrenia

The biochemical womb of schizophrenia: A review

The Effect of Olanzapine Treatment on Monoamine Metabolite Concentrations in the Cerebrospinal Fluid of Schizophrenic Patients

Contact Info

Product

Resources

About